Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis
- Autores:
-
Molina D, Víctor
Álzate V, David
Ruíz B, Jhon
Urrea A, Manuela
Tobón J, Juan
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2014
- Institución:
- Universidad de Córdoba
- Repositorio:
- Repositorio Institucional Unicórdoba
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.unicordoba.edu.co:ucordoba/5303
- Acceso en línea:
- https://repositorio.unicordoba.edu.co/handle/ucordoba/5303
https://doi.org/10.21897/rmvz.91
- Palabra clave:
- Dog
NSAIDS
pain
pharmacology
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by-nc-sa/4.0/
id |
UCORDOBA2_8463a38dcca754e4e49b18884c37791f |
---|---|
oai_identifier_str |
oai:repositorio.unicordoba.edu.co:ucordoba/5303 |
network_acronym_str |
UCORDOBA2 |
network_name_str |
Repositorio Institucional Unicórdoba |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
dc.title.translated.eng.fl_str_mv |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
title |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
spellingShingle |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis Dog NSAIDS pain pharmacology |
title_short |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
title_full |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
title_fullStr |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
title_full_unstemmed |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
title_sort |
Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis |
dc.creator.fl_str_mv |
Molina D, Víctor Álzate V, David Ruíz B, Jhon Urrea A, Manuela Tobón J, Juan |
dc.contributor.author.spa.fl_str_mv |
Molina D, Víctor Álzate V, David Ruíz B, Jhon Urrea A, Manuela Tobón J, Juan |
dc.subject.spa.fl_str_mv |
Dog NSAIDS pain pharmacology |
topic |
Dog NSAIDS pain pharmacology |
publishDate |
2014 |
dc.date.accessioned.none.fl_str_mv |
2014-09-20 00:00:00 2022-06-17T20:08:44Z |
dc.date.available.none.fl_str_mv |
2014-09-20 00:00:00 2022-06-17T20:08:44Z |
dc.date.issued.none.fl_str_mv |
2014-09-20 |
dc.type.spa.fl_str_mv |
Artículo de revista |
dc.type.eng.fl_str_mv |
Journal article |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_6501 |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ARTREF |
dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
format |
http://purl.org/coar/resource_type/c_6501 |
status_str |
publishedVersion |
dc.identifier.issn.none.fl_str_mv |
0122-0268 |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.unicordoba.edu.co/handle/ucordoba/5303 |
dc.identifier.doi.none.fl_str_mv |
10.21897/rmvz.91 |
dc.identifier.url.none.fl_str_mv |
https://doi.org/10.21897/rmvz.91 |
dc.identifier.eissn.none.fl_str_mv |
1909-0544 |
identifier_str_mv |
0122-0268 10.21897/rmvz.91 1909-0544 |
url |
https://repositorio.unicordoba.edu.co/handle/ucordoba/5303 https://doi.org/10.21897/rmvz.91 |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.relation.references.spa.fl_str_mv |
Sanderson RO, Beata C, Flipo R-M, Genevois J-P, Macias C, Tacke S, et al. Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164:418–24. http://dx.doi.org/10.1136/vr.164.14.418 Innes FJ, Cayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 2010 Feb 20;166(1):226–30. http://dx.doi.org/10.1136/vr.c97 Lizarraga Madrigal I, Sumano Lopez H, Castillo Alcala F. Cyclooxygenase-2 selective inhibitors: Potential usage in dogs. Vet Mex. 2002;33(3):2–24. Johnston S, M.McLaughlin R, Budsberg SC. Nonsurgical Management of Osteoar thritis in Dogs. Vet Clin Small Anim. 2008;38:1449–70. http://dx.doi.org/10.1016/j.cvsm.2008.08.001 Aragon CL, Hofmeister EH, Budsberg S. Systematic review of clinical trials of treatments for osteoarthritis in dogs. JAVMA. 2007;230(4):514–21. http://dx.doi.org/10.2460/javma.230.4.514 Henderson AK, Webster CLR. Disruption of the Gastric Mucosal Barrier in Dogs [Internet]. CompendiumVet.com. 2006. Available from: http://cp.vetlearn.com/Media/PublicationsArticle/PV_28_05_340.pdf Nakagawa K, Yamagami T, Takemura N. Hepatocellular toxicosis associated white the alternate administration of carprofen and meloxicam in a siberian husky. j.vet.med.sci. 2005;67(10):1051–3. Batlouni M. Antiinflamatorios No Esteroides: Efectos Cardiovasculares, Cerebrovasculares y Renales. Arq Bras Cardiol. 2010; 94(4):538-46. Autefage A, Palissier FM, Asimus E, Pepin-Richard C. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec. 2011;168:617–23. http://dx.doi.org/10.1136/vr.d1456 Bergh MS, Budsberg S. The coxib NSAIDs: potential clinical and phamacologic importance in veterinary medicine. J Vet Intern Med. 2005;19(1):633–43. http://dx.doi.org/10.1111/j.1939-1676.2005.tb02741.x Choitsu SC, Soen S. Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan. Digestion. 2011;83(1):108–23. Anderson A. Treatment of hip dysplasia. J Small Anim Pract. 2011;52:182–9. http://dx.doi.org/10.1111/j.1748-5827.2011.01049.x Michelin A de F, Ferreira Peres AA, Bitar Galvini B, Lopez Cruz L. Toxicidade renal de inhibidores selectivos da cicloxigenasa 2 : celecoxib e rofecoxib. Rev Ciênc Méd Campinas. 2006;4(15):322–32. Vásquez-Cotés S, Vásquez-Fuertes L, Rodríguez-Alvárez M, Reig-Rincón de Arellano I, Martínez-Cócera C. Tolerancia a celecoxib y meloxicam en pacientes con intolerancia a analgésicos no esteroides. Med Interna. 2008;25(4):163–7. Luna S, Bastilio A, Steagall P. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen and meloxicam in dogs. Am J Vet Res. 2007;68:258–64. http://dx.doi.org/10.2460/ajvr.68.3.258 Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J. 2000;41(1):296–300. Tabibian J, Tabibian N, Kaufman D. Late-onset celecoxib induced combined hepato nephrotoxicity. Br J Clin Pharmacol. 2008;66(1):150–2. http://dx.doi.org/10.1111/j.1365-2125.2008.03157.x Joubert KE. The effects of firocoxib (previcox) in geriatric dogs over a period of 90 days. JSAfr.vetASS. 2009;60(3):179–84. Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3 week and 6 moths dosing of Deracoxib (Deramaxx) chewable tablets in dogs. Jvet Paharmacol Ther. 2008;32(329):337. Agustí A, Danés I. Modificación del efecto antiagregante de ácido acetil salicílico por los fármacos antiinflamatorios no esteroideos. Med Clin Barc. 2004;123(11):433–4. http://dx.doi.org/10.1016/S0025-7753(04)74542-X Goodman L, Gilman A, Hardman J, Limbird LE. Goodman & Gilman’s The Pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2006. Lanas Arbeloa Á. Avances en patología gastrointestinal relacionada con el tratamiento con antiinfl amatorios no esteroideos y antiagregantes plaquetarios. Gastroenterol Hepatol. 2011;34(1):35–42. http://dx.doi.org/10.1016/S0210-5705(11)70005-X Firth AM, Haldane SL. Development of a scale to evaluate postoperative pain in dogs. JAVMA. 1999;214(5):651–9. Gómez LF, Hernánndez CA, Restrepo-Betancurt LF, Orozco S. Comparación de etomidato, ketamina y propofol como inductores para gastroduodenoscopia en perros. Rev Colomb Cienc Pecu. 2007;20(1):59–66. Oddone AJ, Rodríguez-Jurado PM. Enfermedades Congénictas y Hereditarias de las Razas Caninas y Felinas. Primera. Buenos Aires: Intermedica; 2010. 147 p. Hou Y, Wang Y, Lust G, Zhu L, Zhang Z, Todhunter RJ. Retrospective Analysis for Genetic Improvement of Hip Joints of Cohort Labrador Retrievers in the United States: 1970–2007. PLoS ONE. 2010;5(2):9410. http://dx.doi.org/10.1371/journal.pone.0009410 Che Y-F, Jobanputra P, Barton P, Bryan, S, Harris, G, Taylor, RS, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(1):25–32. Llau JV, De Andrés, J J, Gomar C, Gómez-Luque A, Hidalgo F, Sahagún J, et al. Fármacos que alteran la hemostasia y técnicas regionales anestésicas y analgésicas: recomendaciones de seguridad (foro de consenso). R E V Soc Esp Dolor. 2001;8(1):337–48. Campora C, Freeman KP, Lewis FI, Gibson G, Sacchini F, Sanchez-Vazquez MJ. Determination of haematological reference intervals in healthy adult greyhounds. JSAP. 2011 Jun;52(1):301–9. http://dx.doi.org/10.1111/j.1748-5827.2011.01070.x Steagall, P, Mantovani FB, Ferreira TH, Salcedo E, Mouthi-o FQ, Luna LS. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007; 30:2218–23. http://dx.doi.org/10.1111/j.1365-2885.2007.00842.x Chopra S, Kishore-Saini R, Nath-Sanyal S. Intestinal toxicity of non-steroideal anti-inflammatory drugs with differential cyclooxigenase inhibition selectivity. Nutr Hosp. 2007;22(5):528–37. |
dc.relation.bitstream.none.fl_str_mv |
https://revistamvz.unicordoba.edu.co/article/download/91/160 |
dc.relation.citationedition.spa.fl_str_mv |
Núm. 3 , Año 2014 : Revista MVZ Córdoba Volumen 19(3) Septiembre-Diciembre 2014 |
dc.relation.citationendpage.none.fl_str_mv |
4300 |
dc.relation.citationissue.spa.fl_str_mv |
3 |
dc.relation.citationstartpage.none.fl_str_mv |
4289 |
dc.relation.citationvolume.spa.fl_str_mv |
19 |
dc.relation.ispartofjournal.spa.fl_str_mv |
Revista MVZ Córdoba |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Universidad de Córdoba |
dc.source.spa.fl_str_mv |
https://revistamvz.unicordoba.edu.co/article/view/91 |
institution |
Universidad de Córdoba |
bitstream.url.fl_str_mv |
http://172.16.14.198/bitstreams/5054d828-24c0-4d84-b2a5-486bf7ae6016/download |
bitstream.checksum.fl_str_mv |
720720a3f2c0a9d0a2768ee40c6f181c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositorio Universidad de Córdoba |
repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
_version_ |
1812173358476820480 |
spelling |
Molina D, Víctor3986aa5c-e96c-4a7a-aa8c-926d17583883-1Álzate V, David20439bba-0a0b-4f3d-8acd-a555fc903309-1Ruíz B, Jhon185e1e74-c883-48bd-bce8-bc9b00da81f1-1Urrea A, Manuela166dc573-cb47-4ad0-8407-07509eab29f5-1Tobón J, Juan50ab6ee7-780f-416c-ae6d-7fc889589f23-12014-09-20 00:00:002022-06-17T20:08:44Z2014-09-20 00:00:002022-06-17T20:08:44Z2014-09-200122-0268https://repositorio.unicordoba.edu.co/handle/ucordoba/530310.21897/rmvz.91https://doi.org/10.21897/rmvz.911909-0544application/pdfspaUniversidad de Córdobahttps://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2https://revistamvz.unicordoba.edu.co/article/view/91DogNSAIDSpainpharmacologyAnalgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritisAnalgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritisArtículo de revistaJournal articleinfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARTREFhttp://purl.org/coar/version/c_970fb48d4fbd8a85Sanderson RO, Beata C, Flipo R-M, Genevois J-P, Macias C, Tacke S, et al. Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164:418–24. http://dx.doi.org/10.1136/vr.164.14.418Innes FJ, Cayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 2010 Feb 20;166(1):226–30. http://dx.doi.org/10.1136/vr.c97Lizarraga Madrigal I, Sumano Lopez H, Castillo Alcala F. Cyclooxygenase-2 selective inhibitors: Potential usage in dogs. Vet Mex. 2002;33(3):2–24.Johnston S, M.McLaughlin R, Budsberg SC. Nonsurgical Management of Osteoar thritis in Dogs. Vet Clin Small Anim. 2008;38:1449–70. http://dx.doi.org/10.1016/j.cvsm.2008.08.001Aragon CL, Hofmeister EH, Budsberg S. Systematic review of clinical trials of treatments for osteoarthritis in dogs. JAVMA. 2007;230(4):514–21. http://dx.doi.org/10.2460/javma.230.4.514Henderson AK, Webster CLR. Disruption of the Gastric Mucosal Barrier in Dogs [Internet]. CompendiumVet.com. 2006. Available from: http://cp.vetlearn.com/Media/PublicationsArticle/PV_28_05_340.pdfNakagawa K, Yamagami T, Takemura N. Hepatocellular toxicosis associated white the alternate administration of carprofen and meloxicam in a siberian husky. j.vet.med.sci. 2005;67(10):1051–3.Batlouni M. Antiinflamatorios No Esteroides: Efectos Cardiovasculares, Cerebrovasculares y Renales. Arq Bras Cardiol. 2010; 94(4):538-46.Autefage A, Palissier FM, Asimus E, Pepin-Richard C. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec. 2011;168:617–23. http://dx.doi.org/10.1136/vr.d1456Bergh MS, Budsberg S. The coxib NSAIDs: potential clinical and phamacologic importance in veterinary medicine. J Vet Intern Med. 2005;19(1):633–43. http://dx.doi.org/10.1111/j.1939-1676.2005.tb02741.xChoitsu SC, Soen S. Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan. Digestion. 2011;83(1):108–23.Anderson A. Treatment of hip dysplasia. J Small Anim Pract. 2011;52:182–9. http://dx.doi.org/10.1111/j.1748-5827.2011.01049.xMichelin A de F, Ferreira Peres AA, Bitar Galvini B, Lopez Cruz L. Toxicidade renal de inhibidores selectivos da cicloxigenasa 2 : celecoxib e rofecoxib. Rev Ciênc Méd Campinas. 2006;4(15):322–32.Vásquez-Cotés S, Vásquez-Fuertes L, Rodríguez-Alvárez M, Reig-Rincón de Arellano I, Martínez-Cócera C. Tolerancia a celecoxib y meloxicam en pacientes con intolerancia a analgésicos no esteroides. Med Interna. 2008;25(4):163–7.Luna S, Bastilio A, Steagall P. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen and meloxicam in dogs. Am J Vet Res. 2007;68:258–64. http://dx.doi.org/10.2460/ajvr.68.3.258Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J. 2000;41(1):296–300.Tabibian J, Tabibian N, Kaufman D. Late-onset celecoxib induced combined hepato nephrotoxicity. Br J Clin Pharmacol. 2008;66(1):150–2. http://dx.doi.org/10.1111/j.1365-2125.2008.03157.xJoubert KE. The effects of firocoxib (previcox) in geriatric dogs over a period of 90 days. JSAfr.vetASS. 2009;60(3):179–84.Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3 week and 6 moths dosing of Deracoxib (Deramaxx) chewable tablets in dogs. Jvet Paharmacol Ther. 2008;32(329):337.Agustí A, Danés I. Modificación del efecto antiagregante de ácido acetil salicílico por los fármacos antiinflamatorios no esteroideos. Med Clin Barc. 2004;123(11):433–4. http://dx.doi.org/10.1016/S0025-7753(04)74542-XGoodman L, Gilman A, Hardman J, Limbird LE. Goodman & Gilman’s The Pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2006.Lanas Arbeloa Á. Avances en patología gastrointestinal relacionada con el tratamiento con antiinfl amatorios no esteroideos y antiagregantes plaquetarios. Gastroenterol Hepatol. 2011;34(1):35–42. http://dx.doi.org/10.1016/S0210-5705(11)70005-XFirth AM, Haldane SL. Development of a scale to evaluate postoperative pain in dogs. JAVMA. 1999;214(5):651–9.Gómez LF, Hernánndez CA, Restrepo-Betancurt LF, Orozco S. Comparación de etomidato, ketamina y propofol como inductores para gastroduodenoscopia en perros. Rev Colomb Cienc Pecu. 2007;20(1):59–66.Oddone AJ, Rodríguez-Jurado PM. Enfermedades Congénictas y Hereditarias de las Razas Caninas y Felinas. Primera. Buenos Aires: Intermedica; 2010. 147 p.Hou Y, Wang Y, Lust G, Zhu L, Zhang Z, Todhunter RJ. Retrospective Analysis for Genetic Improvement of Hip Joints of Cohort Labrador Retrievers in the United States: 1970–2007. PLoS ONE. 2010;5(2):9410. http://dx.doi.org/10.1371/journal.pone.0009410Che Y-F, Jobanputra P, Barton P, Bryan, S, Harris, G, Taylor, RS, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(1):25–32.Llau JV, De Andrés, J J, Gomar C, Gómez-Luque A, Hidalgo F, Sahagún J, et al. Fármacos que alteran la hemostasia y técnicas regionales anestésicas y analgésicas: recomendaciones de seguridad (foro de consenso). R E V Soc Esp Dolor. 2001;8(1):337–48.Campora C, Freeman KP, Lewis FI, Gibson G, Sacchini F, Sanchez-Vazquez MJ. Determination of haematological reference intervals in healthy adult greyhounds. JSAP. 2011 Jun;52(1):301–9. http://dx.doi.org/10.1111/j.1748-5827.2011.01070.xSteagall, P, Mantovani FB, Ferreira TH, Salcedo E, Mouthi-o FQ, Luna LS. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007; 30:2218–23. http://dx.doi.org/10.1111/j.1365-2885.2007.00842.xChopra S, Kishore-Saini R, Nath-Sanyal S. Intestinal toxicity of non-steroideal anti-inflammatory drugs with differential cyclooxigenase inhibition selectivity. Nutr Hosp. 2007;22(5):528–37.https://revistamvz.unicordoba.edu.co/article/download/91/160Núm. 3 , Año 2014 : Revista MVZ Córdoba Volumen 19(3) Septiembre-Diciembre 201443003428919Revista MVZ CórdobaPublicationOREORE.xmltext/xml2683http://172.16.14.198/bitstreams/5054d828-24c0-4d84-b2a5-486bf7ae6016/download720720a3f2c0a9d0a2768ee40c6f181cMD51ucordoba/5303oai:172.16.14.198:ucordoba/53032023-10-06 00:45:27.902https://creativecommons.org/licenses/by-nc-sa/4.0/metadata.onlyhttp://172.16.14.198Repositorio Universidad de Córdobabdigital@metabiblioteca.com |